FBRX vs INCY
Forte Biosciences, Inc. vs Incyte — AI-powered side-by-side comparison
FBRX
Forte Biosciences, Inc.
59
Watch
VS
| Metric | FBRX | INCY |
|---|
| AI Score |
59
|
72
|
| Price |
$76.88
|
$121.08
|
| P/E Ratio |
-16.78×
|
14.89×
|
| ROE |
-113.7%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
0.0%
|
92.6%
|
| Debt / Equity |
0.00×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
85.6
|
56.2
|
| Beta |
2.645
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for FBRX versus INCY.
INCY leads by 13 points.
INCY scores 72/100 (Buy) versus FBRX at 59/100 (Watch).
FBRX Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 80.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 86 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 92 -- overbought on the larger timeframe too — Technical
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical